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The pathophysiology of chronic Graft-versus-Host Disease
(cGVHD) is complex and poorly understood. Storage of pe-
ripheral blood mononucleated cells (PBMC) for research in
patient cohorts is vital. However, conventional peripheral
blood draws are often insufﬁcient for larger scale immu-
nology studies; in particular, cGVHD patients are frequently
lymphopenic, which further limits an ability to study the role
of relatively rare populations such as Treg cells. To address
this limitation, we evaluated the safety of collecting large
quantities of lymphocytes in cGVHD patients by steady-state
peripheral blood leukapheresis. In total, 132 patients with
cGVHD underwent PBMC collection for research purposes via
leukapheresis performed from 2004 to 2014 on NCI cGVHD
Natural History Protocol, NCT00092235. Various apheresis
machines were used, namely: Baxter CS3000 (n¼63, 47%),
Haemonetics MCS-P (n¼18, 14%), and Terumo SPECTRA
(n¼52, 39%). Median whole blood/anticoagulant (ACDA) ra-
tio was 12:1; median whole blood ﬂow rate (WBFR) was 60
ml/min (35-85); and median product volume was 147 ml
(59-450). Median age was 50 years (18-68). NIH cGVHD
Global scores were moderate (n¼46, 35%) or severe (n¼82,
62%). Mean absolute circulating PBMC level pre-leukaphe-
resis was 2.4 K/mL (0.3-11.6). 22 patients (17%) had an abso-
lute lymphocyte count <1.0 K/ml. A subset of patients (17/
132) had sufﬁciently low pre-leukapheresis peripheral
counts that required special approval for the procedure (Hb
<9.0 g/dL, n¼3; WBC < 3.0 K/mL, n¼5; platelets < 120 K/mL,
n¼9). A two-arm continuous ﬂow apheresis procedure was
used in 108 patients (81%) whereas a one-arm procedurewas
used in 25 patients (8%). Only nine patients underwent leu-
kapheresis via central venous catheter (the remainder were
pheresed using peripheral access). 94 (71%) achieved the
goal collection of 2 x 109 PBMCs, with a mean volume pro-
cessed of 4.6 L. Median total run time was 88 minutes. Mean
number of cells collected and efﬁciencies were: (1) lym-
phocytes, 3.7 x 109, 66.5%; (2) monocytes, 1.1 x 109, 51.1%;
and (3) PBMCs: 4.8 x 109, 59.7%. Mild decreases in abso-
lute peripheral counts were observed, including (median
change 1 hour post-leukapheresis; each value signiﬁcant,
p<0.0001): Hgb: -8%; Plt: -22%; lymphocytes: -26%; and
monocytes: -17%. Grade 1 AEs (CTCAE v4.03) were experi-
enced by 21 patients (16%): hypotension (n¼1, 1%), oral
dysesthesia (n¼10, 8%), paresthesias (n¼6, 5%), anxiety (n¼1,
1%), localized bleeding (n¼2, 2%), and nausea (n¼1, 1%). In
conclusion, we found that steady-state PBMC leukapheresis
represents a safe and effective method for collecting high
numbers of immune cells in patients with moderate-to-se-
vere cGVHD.Wider utilization of leukapheresis in the cGVHD
setting should accelerate immunology research into the
pathogenesis of cGVHD, particularly relating to the role of
relatively rare cell populations.477
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Allogeneic blood and marrow transplantation for the treat-
ment of hematologic malignancies continues to be plaguedby complications such as chronic graft-versus-host disease
(cGVHD), which can occur in upwards of 50% of patients.
Standard therapy involves corticosteroid administration,
which is not always effective and impedes the patient’s re-
turn to a completely competent immune system, thus
increasing the risk of infectious complications. Extracorpo-
real photopheresis (ECP) has been successfully used to abate
cGVHD symptoms in many patients. The effect this therapy
has on lymphocyte subsets in the reconstituting immune
compartment has yet to be fully ascertained. In the pre-
sent study, we used ﬂow cytometric analysis to examine
lymphocyte subsets in patients undergoing ECP for the
treatment of cGVHD. Peripheral blood was collected from 5
patients prior to starting ECP and after 90 days of treatment.
CD4+T cell populations were analyzed for expression of
CD45RA and CCR7 to classify naïve (RA+, CCR7+), central
memory (TCM; RA-, CCR7+), effector memory (TEM; RA-,
CCR7-), and terminally differentiated effector memory
(TEMRA; RA+, CCR7-) T cells. The data reported supports pre-
vious studies which show that all CD4+ T cell populations
analyzed are altered in cGVHD patients (n¼11) compared to
healthy controls (n¼5). In particular, CD4+ TCM and naïve cells
were decreased in cGVHD patients, while CD4+ TEM and
TEMRA were elevated in these patients. Analysis of the same
subsets in cGVHD patients after 90 days of ECP treatment
revealed that the percentage of CD4+ TCMincreased above
baseline levels in the 5 cGVHD patients examined, while
CD4+ TEMRA were decreased during the same time frame. The
increase in CD4+ TCM and the decrease in CD4+ TEMRA were
statistically signiﬁcant as determined by the paired Student’s
t test. Additionally, the ratio of CD4+ TCM to TEM and CD4+ TCM
to TEMRA was calculated in patients before and after ECP
treatment. Results indicate signiﬁcantly increased ratios of
both TCM:TEMand CD4+ TCM:TEMRA in these patients as well.
This data strongly supports the role of ECP in the normali-
zation of CD4+ T cell populations in cGVHD patients.478
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While the ﬁrst-in-disease trials of GvHD prevention with
costimulation blockade add CTLA4-Ig to standard tacrolimus/
methotrexate, previous work has suggested that mTOR in-
hibition with sirolimus is more pro-tolerogenic when paired
with costimulation blockade. We have now investigated
combination CTLA4-Ig + sirolimus to prevent GvHD in the
NHP model, and have interrogated the outcomes using a
systems-based approach. Our experiments provide strong
clinical, immunologic and trancriptomic evidence for potent
synergy when CTLA4-Ig and sirolimus are combined for
GvHD prevention.
We determined the impact of the following treatments on
GvHD after haplo-identical HSCT: 1) no therapy (n¼4) 2)
CTLA4-Ig monotherapy (using belatacept, n¼3) 3) sirolimus
monotherapy (n¼4) 4) combination belatacept and
sirolimus (n¼3). To determine the relative impact of each
therapeutic approach, we monitored clinical GvHD, GvHD-
free survival, and ﬂow cytometric signs of immune activation
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lecular map of their impact on GvHD, we performed tran-
scriptomic analysis, on CD3+/CD20- T cells that were puriﬁed
on day +14.
The synergistic impact of combined belatacept +sirolimus
was evidenced through all analyses techniques: Thus, GvHD-
free survival with belatacept + sirolimus was prolonged
compared to all other groups (MST belatacept + sirolimus ¼
33d, p< 0.02) compared toMST for untreated controls (7.5d),
belatacept monotherapy (9d, p < 0.03) and sirolimus mon-
otherapy (12d, p <0.05), with GvHD clinical scores as well as
canonical ﬂow cytometric signs of CD8+ T cell activation and
excessive cytotoxicity mirroring the clinical survival.
Comparing the expression proﬁle of T cells during acute
GvHD allowed examination of treatment synergy at an un-
precedented level of molecular detail. Unsupervised analysis
revealed clustering of principal components from belatacept
+ sirolimus to be strikingly similar to a large comparative
healthy control cohort (n¼28), underscoring the high
degree of early control of alloreactivity with this regimen.
Moreover, the comparison of differentially expressed genes
from animals receiving belatacept + sirolimus revealed sig-
niﬁcant divergence from monotherapy with either belata-
cept or sirolimus, again underscoring the profound control of
allo-activation that was observed with belatacept + siroli-
mus. Those genes for which expression was signiﬁcantly
normalized showed pathway enrichment prominently in
T cell effector function (prominently including granzyme
signaling), cytokine networks (prominently IL2, IL12 and IL-
18), as well as in proliferation and cell cycle pathways.
These data reveal a treatment synergy between T cell
costimulation blockade with CTLA-4-Ig and mTOR inhibition
and suggest that this combination of therapies will be useful
for acute GvHD immunoprophylaxis in humans.479
Second Allogeneic Hematopoietic Cell Transplantation
Versus Donor Cellular Infusion for Relapse after
Transplant
Betty Ky Hamilton 1, Shylaja Mani 2, Lisa Rybicki 3,
Donna Abounader 1, Steven Andresen 1, Brian Bolwell 1,
Robert M. Dean 1, Hien K. Duong 1, Aaron Gerds 1,
Rabi Hanna 1, Brian Hill 1, Deepa Jagadeesh 1,
Matt E. Kalaycio 1, Brad Pohlman 1, Ronald Sobecks 1,
Navneet S. Majhail 1. 1 Blood & Marrow Transplant Program,
Cleveland Clinic, Cleveland, OH; 2 Internal Medicine, Cleveland
Clinic Foundation, Cleveland, OH; 3Quantitative Health
Sciences, Cleveland Clinic Taussig Cancer Institute, Cleveland,
OH
Disease relapse is still a major cause of treatment failure after
allogeneic hematopoietic cell transplant (HCT). Although
outcomes are still poor, donor cellular infusions (DCI) and
second HCT are still the more commonly used treatment
strategies to treat relapse after transplant. Little is known,
however, regarding the comparable efﬁcacy of either strat-
egy. We thus undertook this retrospective review of patients
relapsing after allogeneic HCT.We identiﬁed 73 patients who
had relapsed after their ﬁrst allogeneic transplant and
received either a DCI (n¼38) or second HCT (n¼35), as
deﬁned by CIBMTR criteria. Patients in the two groups were
matched according to basic demographic information
including gender, race, performance status, comorbidity in-
dex, transplant type, donor source, and diagnosis, which
included both myeloid and lymphoid hematologic malig-
nancies. Patients who underwent a DCI were slightly older,
median 51 years (18-67) compared to thosewho received 2ndtransplant, median 46 years (range 16-66), p¼0.06; and had
a worst grade of GVHD after their ﬁrst transplant, grade 2,
n¼14, 37% for DCI, and n¼5, 14% for 2nd transplant, p¼0.028.
Most patients who underwent DCI received cytoreductive
chemotherapy prior to infusion, n¼24/36 (67%); likewise
patients who underwent 2nd HCT also received some form of
therapy prior to their second procedure, n¼17/34, (50%).
Patients who underwent 2nd transplant had a higher inci-
dence of acute grade 2-4 GVHD, 43% compared to 13% for DCI
at 6 months, p¼0.032, with no signiﬁcant differences in se-
vere grade 3-4 GVHD, p¼0.15. There were also no signiﬁcant
differences in chronic GVHD, 35% for 2nd HCT compared to
26% for DCI at 3 years, p¼0.58. Relapse mortality was
signiﬁcantly higher in recipients of DCI compared to 2nd
transplant, 56% compared to 33%, p¼0.011, respectively;
whereas non-relapse mortality was signiﬁcantly higher in
2nd HCT, 56% compared to 32% in DCI recipients, p¼0.024.
Overall survival at 5 years was similar in both groups, 10% in
2nd HCT recipients versus 12% in DCI recipients, p¼0.44. In
multivariable analysis, months from 1st HCT HR 0.76 per 6
month increase (95% CI 0.62-0.93, p¼0.007) and DCI (HR
2.06, 95% CI 1.02-4.15, p¼0.043) were risk factors for relapse
mortality. Conversely, 2nd HCT was associated with higher
non-relapse mortality compared to DCI (HR 2.38, 95% CI 1.15-
5, p¼0.019). Months from initial transplant (HR 0.92, 95% CI
0.85-0.99, p¼0.028), and blast count prior to second proce-
dure (HR 1.12 per 10% increase, 95% CI 1.02-1.23, p¼0.017)
were the only risk factors for all-cause mortality.
In summary, we found no differences in overall survival
between DCI and 2nd HCT. DCI was associated with higher
relapse mortality, whereas 2nd HCT was associated with
higher non-relapse mortality. Both modalities have poor
survival rates and improved therapeutic options are needed
for relapse after HCT.480
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Aim: The presence of activated CMRF-44+ (Lau, 2007, Trans-
plantation, 83:839) and CCR5+ CD16+ (Shahin, 2013, Trans-
plantation, 96:753) dendritic cells (DC) predicted for acute
graft versus host disease (GVHD) after clinical allogeneic
hematopoietic cell transplantation (alloHCT). We are devel-
oping anti-DC monoclonal antibodies (mAb) as novel
immunosuppressive agents and have shown that polyclonal
